Anti-CBL (phospho Y700) antibody (ab131345)
Key features and details
- Rabbit polyclonal to CBL (phospho Y700)
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-CBL (phospho Y700) antibody
See all CBL primary antibodies -
Description
Rabbit polyclonal to CBL (phospho Y700) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide conjugated to KLH, surrounding the phosphorylation site of tyrosine 700 (
T-E-Y(p)-M-T
) of Human CBL (NP_005179.2). -
Positive control
- HeLa cells; HT29 cell extracts, treated with UV; Human breast carcinoma tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride, 49% PBS
PBS is without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab131345 was purified by using epitope specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
- Cell Biology
- Proteolysis / Ubiquitin
- Proteasome / Ubiquitin
- Ubiquitin E3 Enzymes
- RING Finger E3 Ligase
- Signal Transduction
- Signaling Pathway
- Nuclear Signaling
- Nuclear Hormone Receptors
- Co-activators/co-repressors
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab131345 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 100 kDa). Incubate membrane with diluted antibody in 5% nonfat milk, 1X TBS and 0.1% Tween 20, at 4C, with gentle shaking, overnight.
|
|
IHC-P |
1/50 - 1/100.
|
|
ICC/IF |
1/100 - 1/200.
|
Notes |
---|
WB
1/500 - 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 100 kDa). Incubate membrane with diluted antibody in 5% nonfat milk, 1X TBS and 0.1% Tween 20, at 4C, with gentle shaking, overnight. |
IHC-P
1/50 - 1/100. |
ICC/IF
1/100 - 1/200. |
Target
-
Function
Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. -
Pathway
Protein modification; protein ubiquitination. -
Involvement in disease
Defects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. -
Sequence similarities
Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
Contains 1 RING-type zinc finger.
Contains 1 UBA domain. -
Domain
The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain. -
Post-translational
modificationsPhosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 867 Human
- Entrez Gene: 12402 Mouse
- Entrez Gene: 500985 Rat
- Omim: 165360 Human
- SwissProt: P22681 Human
- SwissProt: P22682 Mouse
- Unigene: 504096 Human
- Unigene: 266871 Mouse
-
Alternative names
- 4732447J05Rik antibody
- C CBL antibody
- Cas Br M (murine) ecotropic retroviral transforming sequence antibody
see all
Images
-
All lanes : Anti-CBL (phospho Y700) antibody (ab131345) at 1/500 dilution
Lane 1 : HT29 cell extracts
Lane 2 : HT29 cell extracts treated with UV
Predicted band size: 100 kDa -
Immunofluorescent analysis of methanol-fixed HeLa cells labelling CBL with ab131345 at 1/100 dilution.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CBL (phospho Y700) antibody (ab131345)Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling CBL with ab131345 at 1/50 dilution, in the absence (left) and presence (right) of the blocking peptide.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab131345 has not yet been referenced specifically in any publications.